Oncolytics Biotech, Inc. (ONCY)
0.7455
-0.03
(-3.43%)
USD |
NASDAQ |
Sep 11, 16:00
0.7519
+0.01
(+0.86%)
After-Hours: 20:00
Oncolytics Biotech Enterprise Value : 89.25M for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 89.25M |
| September 10, 2026 | 92.55M |
| September 09, 2026 | 95.42M |
| September 08, 2026 | 96.67M |
| September 04, 2026 | 101.43M |
| September 03, 2026 | 103.08M |
| September 02, 2026 | 106.01M |
| September 01, 2026 | 101.03M |
| August 31, 2026 | 100.80M |
| August 28, 2026 | 103.10M |
| August 27, 2026 | 102.27M |
| August 26, 2026 | 102.97M |
| August 25, 2026 | 103.70M |
| August 24, 2026 | 101.54M |
| August 21, 2026 | 101.41M |
| August 20, 2026 | 96.25M |
| August 19, 2026 | 99.91M |
| August 18, 2026 | 101.63M |
| August 17, 2026 | 98.87M |
| August 14, 2026 | 100.28M |
| August 13, 2026 | 96.04M |
| August 12, 2026 | 99.00M |
| August 11, 2026 | 98.54M |
| August 10, 2026 | 96.39M |
| August 07, 2026 | 96.35M |
| Date | Value |
|---|---|
| August 06, 2026 | 96.12M |
| August 05, 2026 | 95.69M |
| August 04, 2026 | 97.35M |
| August 03, 2026 | 92.93M |
| July 31, 2026 | 90.22M |
| July 30, 2026 | 90.18M |
| July 29, 2026 | 90.01M |
| July 28, 2026 | 95.06M |
| July 27, 2026 | 96.06M |
| July 24, 2026 | 97.56M |
| July 23, 2026 | 102.06M |
| July 22, 2026 | 99.48M |
| July 21, 2026 | 103.33M |
| July 20, 2026 | 102.27M |
| July 17, 2026 | 102.69M |
| July 16, 2026 | 106.40M |
| July 15, 2026 | 109.01M |
| July 14, 2026 | 109.53M |
| July 13, 2026 | 112.11M |
| July 10, 2026 | 106.92M |
| July 09, 2026 | 111.00M |
| July 08, 2026 | 95.08M |
| July 07, 2026 | 103.00M |
| July 06, 2026 | 106.04M |
| July 02, 2026 | 108.39M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 11.47B |
| Sangamo Therapeutics, Inc. | 53.27M |
| Sarepta Therapeutics, Inc. | 2.417B |
| Anixa Biosciences, Inc. | 80.49M |
| Vicapsys Life Sciences, Inc. | 32.86M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -9.442M |
| Total Expenses (Quarterly) | 9.442M |
| EPS Diluted (Quarterly) | -0.0788 |
| Earnings Yield | -36.55% |
| Normalized Earnings Yield | -36.61 |